Skip to main content
. 2024 Dec 7;25(23):13153. doi: 10.3390/ijms252313153

Figure 1.

Figure 1

sNfL (picograms/mL) of RRMS patients and healthy controls at baseline, 6 and 12 months of Natalizumab; sGFAP (picograms/mL) of RRMS patients and healthy controls at baseline, 6 and 12 months of Natalizumab. ** (p = 0.006), **** (p < 0.0001).